Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2004 1
2005 4
2006 4
2007 4
2008 2
2009 2
2010 2
2011 4
2012 8
2013 14
2014 15
2015 11
2016 12
2017 9
2018 9
2019 6
2020 3
2021 2
2022 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Results by year

Filters applied: . Clear all
Page 1
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Schwartz GG, et al. Among authors: tricoci p. N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7. N Engl J Med. 2018. PMID: 30403574 Free article. Clinical Trial.
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.
Gibson CM, Kastelein JJP, Phillips AT, Aylward PE, Yee MK, Tendera M, Nicholls SJ, Pocock S, Goodman SG, Alexander JH, Lincoff AM, Bode C, Duffy D, Heise M, Berman G, Mears SJ, Tricoci P, Deckelbaum LI, Steg PG, Ridker P, Mehran R. Gibson CM, et al. Among authors: tricoci p. Am Heart J. 2021 Jan;231:121-127. doi: 10.1016/j.ahj.2020.10.052. Epub 2020 Oct 13. Am Heart J. 2021. PMID: 33065120 Free article.
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future.
Kalayci A, Gibson CM, Ridker PM, Wright SD, Kingwell BA, Korjian S, Chi G, Lee JJ, Tricoci P, Kazmi SH, Fitzgerald C, Shaunik A, Berman G, Duffy D, Libby P. Kalayci A, et al. Among authors: tricoci p. Curr Atheroscler Rep. 2022 Jul;24(7):585-597. doi: 10.1007/s11883-022-01025-7. Epub 2022 May 7. Curr Atheroscler Rep. 2022. PMID: 35524914 Free PMC article. Review.
A new generation of antiplatelet agents.
Sellers MB, Tricoci P, Harrington RA. Sellers MB, et al. Among authors: tricoci p. Curr Opin Cardiol. 2009 Jul;24(4):307-12. doi: 10.1097/HCO.0b013e32832e2b44. Curr Opin Cardiol. 2009. PMID: 19509485 Review.
Promises of PAR-1 inhibition in acute coronary syndrome.
Leonardi S, Tricoci P, Mahaffey KW. Leonardi S, et al. Among authors: tricoci p. Curr Cardiol Rep. 2012 Feb;14(1):32-9. doi: 10.1007/s11886-011-0232-z. Curr Cardiol Rep. 2012. PMID: 22160877 Review.
Effect of Alirocumab on Mortality After Acute Coronary Syndromes.
Steg PG, Szarek M, Bhatt DL, Bittner VA, Brégeault MF, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Ostadal P, Parkhomenko A, Pordy R, Roe MT, Tricoci P, Vogel R, White HD, Zeiher AM, Schwartz GG. Steg PG, et al. Among authors: tricoci p. Circulation. 2019 Jul 9;140(2):103-112. doi: 10.1161/CIRCULATIONAHA.118.038840. Epub 2019 May 23. Circulation. 2019. PMID: 31117810 Free PMC article. Clinical Trial.
102 results